Abstract: Provided is a kit comprising a compound having vitamin B-12 activity in a form that is suitable for injection. The kit can be in the form of a box with a lid with a number of components placed in the box. The compound having vitamin B-12 activity can be cyanocobalamin, typically in form of a solution in a vial. The kit can contain an alcohol pad. The kit can contain a pair of gloves. The kit can contain a csr wrap. The concentration of the cyanocobalamin can be 1000 mcg/ml. In one embodiment, the kit is a box with a lid and following components placed inside of the box: a) a container having 1 milliliter (mL) of a solution of cyanocobalamin with a concentration of 1000 mcg/ml; b) isopropyl pad; c) a pair of gloves; and d) a csr wrap.

Abstract: Provided are kits containing a base composition and an active pharmaceutical ingredient for transdermal delivery of active pharmaceutical ingredients. Examples of active pharmaceutical ingredients include amitriptyline, baclofen, cyclobenzaprine HCl, ibuprofen, lidocaine HCl, naproxen, and tramadol, ketoprofen, diclofenac, phenylbutazone, mefenamic acid, flubiprofen, piroxicam, guaifenasin, prilocaine, bupivicaine, tetracaine, nifedipine, verapamil, orphenadrine, imipramine, ketamine, gabapentin, carbamazepine, menthol, capsaicin, clonidine, dexamethasone, dextromethorphan, testosterone, progesterone, and estrogens.

Abstract: Provided a kit with all the necessary components for a medical practitioner in the office practice setting to inject testosterone to a patient. Specifically, the kit can include a holder and following components placed inside a holder: a) a container of testosterone ester in a formulation that is suitable for injection to an animal; b) a pad for disinfecting or cleaning an injection site; and c) a pair of gloves.

Abstract: Provides is a kit comprising: a) a container; and b) following components placed inside of the container: i) magnesium citrate oral Solution; ii) a laxative in form of an oral pharmaceutical dosage form; iii) a topical formulation for application to the skin to relieve irritation; iii) a container of polyethylene glycol powder; iv) an oral pharmaceutical dosage form for treating nausea; and v) an electrolyte drink mix; wherein the kit is used by a patient to clean the patient's colon prior to a colonoscopy.

Abstract: The present invention is directed to co-administration of hydrocodone and a second analgesic agent for the treatment of pain. A pharmaceutical composition suitable for the co-administration contains a therapeutically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of at least one second analgesic agent. A ratio of the hydrocodone or pharmaceutically acceptable salt thereof to the at least one second analgesic agent in the composition is within a range that provides greater pain relief than that obtainable by the administration of the hydrocodone or second analgesic agent alone. Examples of pharmaceutical compositions for co-administration of the agents are those containing hydrocodone and indomethacin (“Indocodone”), hydrocodone and naproxen (“Naprocodone”), hydrocodone and diclofenac (“Diclodone”) and hydrocodone and tramadol (“Tramacodone”).

Abstract: The present invention is directed to co-administration of a non-steroidal anti-inflammatory agent (NSAID) and acetaminophen for the treatment of pain and inflammation with reduced gastrointestinal irritation. A pharmaceutical composition suitable for the co-administration contains a therapeutically effective amount of at least one non-steroidal anti-inflammatory agent, and a therapeutically effective amount of acetaminophen or a pharmaceutically acceptable salt thereof. A ratio of the non-steroidal anti-inflammatory agent to acetaminophen in the composition is within a range that provides greater pain relief and reduction of inflammation with less gastrointestinal irritation than that obtainable by the administration of the non-steroidal anti-inflammatory agent or acetaminophen alone. Examples of pharmaceutical compositions for co-administration of the agents are those containing ibuprofen in combination with the acetaminophen.

Abstract: The present invention is directed to co-administration of a non-steroidal anti-inflammatory agent (NSAID) and acid blocking agent for the treatment of pain and inflammation with reduced gastrointestinal irritation. A pharmaceutical composition suitable for the co-administration contains a therapeutically effective amount of at least one non-steroidal anti-inflammatory agent, and a therapeutically effective amount of at least one acid blocking agent. A ratio of the non-steroidal anti-inflammatory agent to acid blocking agent in the composition is within a range that provides greater pain relief and reduction of inflammation with less gastrointestinal irritation than that obtainable by the administration of the non-steroidal anti-inflammatory agent or acid blocking agent alone. Examples of pharmaceutical compositions for co-administration of the agents are those containing ibuprofen and ranitidine (“ibudine”), as well as naproxen and ranitidine (“naprodine”).